Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-26T12:32:46.128Z Has data issue: false hasContentIssue false

Chapter 9 - Anxiety in Parkinson’s Disease

Published online by Cambridge University Press:  08 March 2021

By
Nadeeka N. W. Dissanayaka
Edited by
Gerard J. Byrne  and
Nancy A. Pachana
Gerard J. Byrne
Affiliation:
University of Queensland
Nancy A. Pachana
Affiliation:
University of Queensland
Get access

Summary

Parkinson’s disease (PD) is a chronic, progressive, and disabling neurological disorder. The incidence of PD increases with age, and therefore the disease is predominantly observed in later life. The prevalence of PD is estimated at 1% in individuals aged 60 years and over, 2–3% in those aged 65 years and over, and 10% in those aged 80 years and over (de Rijk et al., 1997). In clinical practice, PD is classified as a movement disorder and is characterized by motor symptoms such as tremor, rigidity, bradykinesia, postural instability, and gait dysfunction. However, there are a large number of non-motor symptoms observed in PD, including neuropsychiatric complications, sleep disorders, fatigue, sensory symptoms, autonomic dysfunction, and gastrointestinal symptoms (Chaudhuri et al., 2011).

Type
Chapter
Information
Anxiety in Older People
Clinical and Research Perspectives
 , pp. 139 - 156
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

A’Campo, L. E., Wekking, E. M., Spliethoff-Kamminga, N. G., Le Cessie, S. and Roos, R. A. (2010). The benefits of a standardized patient education program for patients with Parkinson’s disease and their caregivers. Parkinsonism & Related Disorders, 16, 89–95.CrossRefGoogle ScholarPubMed
Advocat, J., Enticott, J., Vandenberg, B., Hassed, C., Hester, J. and Russell, G. (2016). The effects of a mindfulness-based lifestyle program for adults with Parkinson’s disease: a mixed methods, wait list controlled randomised control study. BMC Neurology, 16, 166.CrossRefGoogle ScholarPubMed
Advocat, J., Russell, G., Enticott, J., Hassed, C., Hester, J. and Vandenberg, B. (2013). The effects of a mindfulness-based lifestyle programme for adults with Parkinson’s disease: protocol for a mixed methods, randomised two-group control study. BMJ Open, 3, e003326.CrossRefGoogle ScholarPubMed
Ambermoon, P., Carter, A., Hall, W., Dissanayaka, N. and O’Sullivan, J. (2011). Impulse control disorders in patients with Parkinson’s disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction, 106, 283–293.Google Scholar
Ambermoon, P., Carter, A., Hall, W., Dissanayaka, N. and O’Sullivan, J. (2012). Compulsive use of dopamine replacement therapy: a model for stimulant drug addiction? Addiction, 107, 241–247.Google Scholar
Armento, M. E. A., Stanley, M. A., Marsh, L., et al. (2012). Cognitive behavioral therapy for depression and anxiety in Parkinson’s disease: a clinical review. Journal of Parkinson’s Disease, 2, 135–151.Google Scholar
Birtwell, K., Dubrow-Marshall, L., Dubrow-Marshall, R., Duerden, T. and Dunn, A. (2017). A mixed methods evaluation of a mindfulness-based stress reduction course for people with Parkinson’s disease. Complementary Therapies in Clinical Practice, 29, 220–228.Google Scholar
Bloem, B. R., Grimbergen, Y. A., Cramer, M., Willemsen, M. and Zwinderman, A. H. (2001). Prospective assessment of falls in Parkinson’s disease. Journal of Neurology, 248, 950–958.CrossRefGoogle ScholarPubMed
Bogdanova, Y. and Cronin-Golomb, A. (2012). Neurocognitive correlates of apathy and anxiety in Parkinson’s disease. Parkinson’s Disease 2012, 793076.Google Scholar
Bogosian, A., Hurt, C. S., Vasconcelos, E. S. D., Hindle, J. V., McCracken, L. and Cubi-Molla, P. (2017). Distant delivery of a mindfulness-based intervention for people with Parkinson’s disease: the study protocol of a randomised pilot trial. Pilot and Feasibility Studies, 3, 4.Google Scholar
Bolluk, B., Ozel-Kizil, E. T., Akbostanci, M. C. and Atbasoglu, E. C. (2010). Social anxiety in patients with Parkinson’s disease. Journal of Neuropsychiatry and Clinical Neurosciences, 22, 390–394.Google Scholar
Bower, J. H., Grossardt, B. R., Maraganore, D. M., et al. (2010). Anxious personality predicts an increased risk of Parkinson’s disease. Movement Disorders, 25, 2105–2113.CrossRefGoogle ScholarPubMed
Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H. and Del Tredici, K. (2004). Stages in the development of Parkinson’s disease-related pathology. Cell and Tissue Research, 318, 121–134.Google Scholar
Broen, M. P., Narayen, N. E., Kuijf, M. L., Dissanayaka, N. N. and Leentjens, A. F. (2016). Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Movement Disorders, 31, 1125–1133.CrossRefGoogle ScholarPubMed
Brown, R. G., Landau, S., Hindle, J. V., et al. (2011). Depression and anxiety related subtypes in Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry, 82, 803–809.Google Scholar
Burn, D. J., Landau, S., Hindle, J. V., et al. (2012). Parkinson’s disease motor subtypes and mood. Movement Disorders, 27, 379–386.Google Scholar
Casacchia, M., Zamponi, A., Squitieri, G. and Meco, G. (1975). Treatment of anxiety in Parkinson’s disease with bromazepam. Rivista di Neurologia, 45, 326–338.Google Scholar
Castrioto, A., Lhommee, E., Moro, E. and Krack, P. (2014). Mood and behavioural effects of subthalamic stimulation in Parkinson’s disease. Lancet Neurology, 13, 287–305.CrossRefGoogle ScholarPubMed
Ceravolo, R., Frosini, D., Poletti, M., et al. (2013). Mild affective symptoms in de novo Parkinson’s disease patients: relationship with dopaminergic dysfunction. European Journal of Neurology, 20, 480–485.Google Scholar
Chaudhuri, K. R., Odin, P., Antonini, A. and Martinez-Martin, P. (2011). Parkinson’s disease: the non-motor issues. Parkinsonism & Related Disorders, 17, 717–723.CrossRefGoogle ScholarPubMed
Chen, J. J. and Marsh, L. (2014). Anxiety in Parkinson’s disease: identification and management. Therapeutic Advances in Neurological Disorders, 7, 52–59.Google Scholar
Chen, Y. K., Lu, J. Y., Chan, D. M., et al. (2010). Anxiety disorders in Chinese patients with Parkinson’s disease. International Journal of Psychiatry in Medicine, 40, 97–107.CrossRefGoogle ScholarPubMed
Chuang, C. and Fahn, S. (2001). Dramatic benefit with clonazepam treatment of intractable anxiety and panic attacks in Parkinson’s disease [abstract]. Movement Disorders, 16, S35.Google Scholar
Connolly, B. and Fox, S. H. (2014). Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson’s disease. Neurotherapeutics, 11, 78–91.Google Scholar
Cumming, R. G. and Le Couteur, D. G. (2003). Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs, 17, 825–837.Google Scholar
de Rijk, M. C., Tzourio, C., Breteler, M. M., et al. (1997). Prevalence of Parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry, 62, 10–15.CrossRefGoogle ScholarPubMed
Del Tredici, K. and Braak, H. (2013). Dysfunction of the locus coeruleus–norepinephrine system and related circuitry in Parkinson’s disease-related dementia. Journal of Neurology, Neurosurgery, and Psychiatry, 84, 774–783.Google Scholar
Dissanayaka, N. N., Idu Jion, F., Pachana, N. A., et al. (2016a). Mindfulness for motor and nonmotor dysfunctions in Parkinson’s disease. Parkinson’s Disease, 2016, 7109052.Google ScholarPubMed
Dissanayaka, N. N. W., O’Sullivan, J. D., Pachana, N. A., et al. (2016b). Disease specific anxiety symptoms in Parkinson’s disease International Psychogeriatrics, 28, 1153–1163.Google Scholar
Dissanayaka, N. N. W., Pye, D., Mitchell, L. K., et al. (2017). Cognitive behavior therapy for anxiety in Parkinson’s disease: outcomes for patients and caregivers. Clinical Gerontology, 40, 159–171.Google Scholar
Dissanayaka, N. N. W., Sellbach, A., Matheson, S., et al. (2010). Anxiety disorders in Parkinson’s disease: prevalence and risk factors. Movement Disorders, 25, 838–845.Google Scholar
Dissanayaka, N. N. W., Torbey, E. and Pachana, N. (2015a). Anxiety rating scales in Parkinson’s disease: a critical review updating recent literature. International Psychogeriatrics, 27, 1777–1784.Google Scholar
Dissanayaka, N. N. W., White, E., O’Sullivan, J. D., Marsh, R., Pachana, N. A. and Byrne, G. J. (2014). The clinical spectrum of anxiety in Parkinson’s disease. Movement Disorders, 29, 967–975.Google Scholar
Dissanayaka, N. N. W., White, E., O’Sullivan, J. D., et al. (2015b). Characteristics and treatment of anxiety disorders in Parkinson’s disease. Movement Disorders Clinical Practice, 2, 155–162.Google Scholar
Djamshidian, A. and Friedman, J. H. (2014). Anxiety and depression in Parkinson’s disease. Current Treatment Options in Neurology, 16, 285.Google Scholar
Dobkin, R. D., Allen, L. A. and Menza, M. (2007). Cognitive-behavioral therapy for depression in Parkinson’s disease: a pilot study. Movement Disorders, 22, 946–52.Google Scholar
Dobkin, R. D., Menza, M., Allen, L. A., et al. (2011a). Cognitive–behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. American Journal of Psychiatry, 168, 1066–1074.Google Scholar
Dobkin, R. D., Menza, M., Allen, L. A., et al. (2011b). Telephone-based cognitive–behavioral therapy for depression in Parkinson disease. Journal of Geriatric Psychiatry and Neurology, 24, 206–214.Google Scholar
Dobkin, R. D., Rubino, J. T., Allen, L. A., et al. (2012). Predictors of treatment response to cognitive–behavioral therapy for depression in Parkinson’s disease. Journal of Consulting and Clinical Psychology, 80, 694–699.Google Scholar
Erdal, K. J. (2001). Depression and anxiety in persons with Parkinson’s disease with and without ‘on–off’ phenomena. Journal of Clinical Psychology in Medical Settings, 8, 293–299.CrossRefGoogle Scholar
Erro, R., Pappata, S., Amboni, M., et al. (2012). Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson’s disease patients. Parkinsonism & Related Disorders, 18, 1034–1038.Google Scholar
Feeney, F., Egan, S. and Gasson, N. (2005). Treatment of depression and anxiety in Parkinson’s disease: a pilot study using group cognitive behavioural therapy. Clinical Psychologist, 9, 31–38.Google Scholar
Fitzpatrick, L., Simpson, J. and Smith, A. (2010). A qualitative analysis of mindfulness-based cognitive therapy (MBCT) in Parkinson’s disease. Psychology and Psychotherapy, 83, 179–192.Google Scholar
Forjaz, M. J., Martinez-Martin, P., Dujardin, K., et al. (2013). Rasch analysis of anxiety scales in Parkinson’s disease. Journal of Psychosomatic Research, 74, 414–419.Google Scholar
Gallagher, D. A., Goetz, C. G., Stebbins, G., Lees, A. J. and Schrag, A. (2012). Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson’s disease. Movement Disorders, 27, 79–83.Google Scholar
George, S., Van Den Buuse, M., San Mok, S., Masters, C. L., Li, Q. X. and Culvenor, J. G. (2008). Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour. Experimental Neurology, 210, 788–792.CrossRefGoogle ScholarPubMed
Graham, D. R. and Sidhu, A. (2010). Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior. Journal of Neuroscience Research, 88, 1777–1783.Google Scholar
Harding, A. J., Stimson, E., Henderson, J. M. and Halliday, G. M. (2002). Clinical correlates of selective pathology in the amygdala of patients with Parkinson’s disease. Brain, 125, 2431–2445.Google Scholar
Heinrichs, N., Hoffman, E. C. and Hofmann, S. G. (2001). Cognitive–behavioral treatment for social phobia in Parkinson’s disease: a single-case study. Cognitive and Behavioral Practice, 8, 328–335.CrossRefGoogle ScholarPubMed
Hu, M., Cooper, J., Beamish, R., et al. (2011). How well do we recognise non-motor symptoms in a British Parkinson’s disease population? Journal of Neurology, 258, 1513–1517.CrossRefGoogle Scholar
Huang, C., Ravdin, L. D., Nirenberg, M. J., et al. (2013). Neuroimaging markers of motor and nonmotor features of Parkinson’s disease: an 18F fluorodeoxyglucose positron emission computed tomography study. Dementia and Geriatric Cognitive Disorders, 35, 183–196.CrossRefGoogle ScholarPubMed
Hyman, C., Hofer, M., Barde, Y. A., et al. (1991). BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature, 350, 230–232.Google Scholar
Jacob, E. L., Gatto, N. M., Thompson, A., Bordelon, Y. and Ritz, B. (2010). Occurrence of depression and anxiety prior to Parkinson’s disease. Parkinsonism & Related Disorders, 16, 576–81.Google Scholar
Khedr, E. M., El Fetoh, N. A., Khalifa, H., Ahmed, M. A. and El Beh, K. M. A. (2012). Prevalence of depression, anxiety, dementia and other non motor features of a large cohort of Egyptian Parkinson’s disease patients. Life Science Journal, 9, 509–518.Google Scholar
Kim, S., Park, J. M., Moon, J. and Choi, H. J. (2014). Alpha-synuclein interferes with cAMP/PKA-dependent upregulation of dopamine beta-hydroxylase and is associated with abnormal adaptive responses to immobilization stress. Experimental Neurology, 252, 63–74.Google Scholar
Kraepelien, M., Svenningsson, P., Lindefors, N. and Kaldo, V. (2015). Internet-based cognitive behavioral therapy for depression and anxiety in Parkinson’s disease – a pilot study. Internet Interventions, 2, 1–6.CrossRefGoogle Scholar
Kulisevsky, J., Pagonabarraga, J., Pascual-Sedano, B., Garcia-Sanchez, C. and Gironell, A. (2008). Prevalence and correlates of neuropsychiatric symptoms in Parkinson’s disease without dementia. Movement Disorders, 23, 1889–1896.Google Scholar
Kulisevsky, J., Pascual-Sedano, B., Barbanoj, M., Gironell, A., Pagonabarraga, J. and Garcia-Sanchez, C. (2007). Acute effects of immediate and controlled-release levodopa on mood in Parkinson’s disease: a double-blind study. Movement Disorders, 22, 62–67.Google Scholar
Kummer, A., Cardoso, F. and Teixeira, A. L. (2008). Frequency of social phobia and psychometric properties of the Liebowitz social anxiety scale in Parkinson’s disease. Movement Disorders, 23, 1739–1743.Google Scholar
Kummer, A., Cardoso, F. and Teixeira, A. L. (2010). Generalized anxiety disorder and the Hamilton Anxiety Rating Scale in Parkinson’s disease. Arquivos de Neuro-Psiquiatria, 68, 495–501.CrossRefGoogle ScholarPubMed
Lauterbach, E. C., Freeman, A. and Vogel, R. L. (2003). Correlates of generalized anxiety and panic attacks in dystonia and Parkinson disease. Cognitive and Behavioral Neurology, 16, 225–233.Google Scholar
Lauterbach, E. C., Freeman, A. and Vogel, R. L. (2004). Differential DSM-III psychiatric disorder prevalence profiles in dystonia and Parkinson’s disease. Journal of Neuropsychiatry and Clinical Neurosciences, 16, 29–36.Google Scholar
Leentjens, A. F., Dujardin, K., Marsh, L., Martinez-Martin, P., Richard, I. H. and Starkstein, S. E. (2012). Anxiety and motor fluctuations in Parkinson’s disease: a cross-sectional observational study. Parkinsonism & Related Disorders, 18, 1084–1088.Google Scholar
Leentjens, A. F., Dujardin, K., Marsh, L., Richard, I. H., Starkstein, S. E. and Martinez-Martin, P. (2011). Anxiety rating scales in Parkinson’s disease: a validation study of the Hamilton Anxiety Rating Scale, the Beck Anxiety Inventory, and the Hospital Anxiety and Depression Scale. Movement Disorders, 26, 407–415.CrossRefGoogle ScholarPubMed
Leentjens, A. F., Dujardin, K., Pontone, G. M., Starkstein, S. E., Weintraub, D. and Martinez-Martin, P. (2014). The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale. Movement Disorders, 29, 1035–1043.CrossRefGoogle ScholarPubMed
Leentjens, A. F., Dujardin, K., Marsh, L., et al. (2008). Anxiety rating scales in Parkinson’s disease: critique and recommendations. Movement Disorders, 23, 2015–2025.Google Scholar
Macht, M., Schwarz, R. and Ellgring, H. (2005). Patterns of psychological problems in Parkinson’s disease. Acta Neurologica Scandinavica, 111, 95–101.CrossRefGoogle ScholarPubMed
Manor, Y., Balas, M., Giladi, N., Mootanah, R. and Cohen, J. T. (2009). Anxiety, depression and swallowing disorders in patients with Parkinson’s disease. Parkinsonism & Related Disorders, 15, 453–456.Google Scholar
Marinus, J., Leentjens, A. F., Visser, M., Stiggelbout, A. M. and Van Hilten, J. J. (2002). Evaluation of the hospital anxiety and depression scale in patients with Parkinson’s disease. Clinical Neuropharmacology, 25, 318–324.CrossRefGoogle ScholarPubMed
Marxreiter, F., Ettle, B., May, V. E., et al. (2013). Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice. Neurobiology of Disease, 59, 38–51.Google Scholar
Matheson, S. F., Byrne, G. J., Dissanayaka, N. N., et al. (2012). Validity and reliability of the Geriatric Anxiety Inventory in Parkinson’s disease. Australasian Journal on Ageing, 31, 13–16.Google Scholar
Matsui, H., Nishinaka, K., Oda, M., et al. (2007). Depression in Parkinson’s disease. diffusion tensor imaging study. Journal of Neurology, 254, 1170–1173.CrossRefGoogle ScholarPubMed
McLean, G., Lawrence, M., Simpson, R. and Mercer, S. W. (2017). Mindfulness-based stress reduction in Parkinson’s disease: a systematic review. BMC Neurology, 17, 92.Google Scholar
Menza, M., Marin, H., Kaufman, K., Mark, M. and Lauritano, M. (2004). Citalopram treatment of depression in Parkinson’s disease: the impact on anxiety, disability, and cognition. Journal of Neuropsychiatry and Clinical Neurosciences, 16, 315–319.CrossRefGoogle ScholarPubMed
Menza, M. A., Palermo, B., Dipaola, R., Sage, J. I. and Ricketts, M. H. (1999). Depression and anxiety in Parkinson’s disease: possible effect of genetic variation in the serotonin transporter. Journal of Geriatric Psychiatry and Neurology, 12, 49–52.Google Scholar
Menza, M. A., Robertson-Hoffman, D. E. and Bonapace, A. S. (1993). Parkinson’s disease and anxiety: comorbidity with depression. Biological Psychiatry, 34, 465–470.Google Scholar
Mohlman, J., Reel, D. H., Chazin, D., et al. (2010). A novel approach to treating anxiety and enhancing executive skills in an older adult with Parkinson’s disease. Clinical Case Studies, 9, 74–90.Google Scholar
Mondolo, F., Jahanshahi, M., Granà, A., Biasutti, E., Cacciatori, E. and Di Benedetto, P. (2007). Evaluation of anxiety in Parkinson’s disease with some commonly used rating scales. Neurological Sciences, 28, 270–275.Google Scholar
Moonen, A. J., Wijers, A., Leentjens, A. F., et al. (2014). Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson’s disease. Parkinsonism & Related Disorders, 20, 644–646.Google Scholar
Moriyama, T. S., Felicio, A. C., Chagas, M. H., et al. (2011). Increased dopamine transporter density in Parkinson’s disease patients with social anxiety disorder. Journal of the Neurological Sciences, 310, 53–57.Google Scholar
Negre-Pages, L., Grandjean, H., Lapeyre-Mestre, M., et al. (2010). Anxious and depressive symptoms in Parkinson’s disease: the French cross-sectional DoPaMiP study. Movement Disorders, 25, 157–166.Google Scholar
Okai, D., Askey-Jones, S., Samuel, M., et al. (2013). Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology, 80, 792–799.Google Scholar
Ozdilek, B. and Gunal, D. I. (2012). Motor and non-motor symptoms in Turkish patients with Parkinson’s disease affecting family caregiver burden and quality of life. Journal of Neuropsychiatry and Clinical Neurosciences, 24, 478–483.Google Scholar
Pachana, N. A., Byrne, G. J., Siddle, H., Koloski, N., Harley, E. and Arnold, E. (2007). Development and validation of the Geriatric Anxiety Inventory. International Psychogeriatrics, 19, 103–114.CrossRefGoogle ScholarPubMed
Pachana, N. A., Egan, S. J., Laidlaw, K., et al. (2013). Clinical issues in the treatment of anxiety and depression in older adults with Parkinson’s disease. Movement Disorders, 28, 1930–1934.Google Scholar
Pena-Oliver, Y., Buchman, V. L. and Stephens, D. N. (2010). Lack of involvement of alpha-synuclein in unconditioned anxiety in mice. Behavioural Brain Research, 209, 234–240.Google Scholar
Peron, J., Dondaine, T., Le Jeune, F., Grandjean, D. and Verin, M. (2012). Emotional processing in Parkinson’s disease: a systematic review. Movement Disorders, 27, 186–199.Google Scholar
Picillo, M., Amboni, M., Erro, R., et al. (2013). Gender differences in non-motor symptoms in early, drug naive Parkinson’s disease. Journal of Neurology, 260, 2849–2855.Google Scholar
Pickut, B. and Vanneste, S. (2015). Mindfulness training among individuals with Parkinson’s disease: neurobehavioral effects. Hindawi, 2015, 816404.Google Scholar
Pickut, B., Vanneste, S., Hirsch, M. A., et al. (2015). Mindfulness training among individuals with Parkinson’s disease: neurobehavioral effects. Parkinson’s Disease, 2015, 816404.Google Scholar
Pontone, G. M., Williams, J. R., Anderson, K. E., et al. (2009). Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson’s disease. Movement Disorders, 24, 1333–1338.Google Scholar
Prediger, R. D., Matheus, F. C., Schwarzbold, M. L., Lima, M. M. and Vital, M. A. (2012). Anxiety in Parkinson’s disease: a critical review of experimental and clinical studies. Neuropharmacology, 62, 115–124.Google Scholar
Qureshi, S. U., Amspoker, A. B., Calleo, J. S., Kunik, M. E. and Marsh, L. (2012). Anxiety disorders, physical illnesses, and health care utilization in older male veterans with Parkinson disease and comorbid depression. Journal of Geriatric Psychiatry and Neurology, 25, 233–239.Google Scholar
Rahman, S., Griffin, H. J., Quinn, N. P. and Jahanshahi, M. (2011). On the nature of fear of falling in Parkinson’s disease. Behavioural Neurology, 24, 219–228.Google Scholar
Remy, P., Doder, M., Lees, A., Turjanski, N. and Brooks, D. (2005). Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain, 128, 1314–1322.Google Scholar
Richard, I. H., Frank, S., McDermott, M. P., et al. (2004). The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations. Cognitive and Behavioral Neurology, 17, 201–207.Google Scholar
Richard, I. H., McDermott, M. P., Kurlan, R., et al. (2012). A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology, 78, 1229–1236.Google Scholar
Rodriguez-Blazquez, C., Frades-Payo, B., Forjaz, M. J., De Pedro-Cuesta, J. and Martinez-Martin, P. (2009). Psychometric attributes of the Hospital Anxiety and Depression Scale in Parkinson’s disease. Movement Disorders, 24, 519–525.CrossRefGoogle ScholarPubMed
Rodriguez-Violante, M., Cervantes-Arriaga, A., Corona, T., Martinez-Ramirez, D., Morales-Briceno, H. and Martinez-Martin, P. (2013). Clinical determinants of health-related quality of life in Mexican patients with Parkinson’s disease. Archives of Medical Research, 44, 110–114.Google Scholar
Rothman, S. M., Griffioen, K. J., Vranis, N., et al. (2013). Neuronal expression of familial Parkinson’s disease A53T alpha-synuclein causes early motor impairment, reduced anxiety and potential sleep disturbances in mice. Journal of Parkinson’s Disease, 3, 215–229.Google Scholar
Schrag, A., Jahanshahi, M. and Quinn, N. (2000). How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Movement Disorders, 15, 1112–1118.Google Scholar
Shiba, M., Bower, J. H., Maraganore, D. M., et al. (2000). Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case–control study. Movement Disorders, 15, 669–677.Google Scholar
Shulman, L. M., Singer, C., Bean, J., et al. (1996). Therapeutic effects of sertraline in patients with Parkinson’s disease [abstract]. Movement Disorders, 11, 12.Google Scholar
Shulman, L. M., Taback, R. L., Bean, J. and Weiner, W. J. (2001). Comorbidity of the nonmotor symptoms of Parkinson’s disease. Movement Disorders, 16, 507–510.Google Scholar
Siemers, E. R., Shekhar, A., Quaid, K. and Dickson, H. (1993). Anxiety and motor performance in Parkinson’s disease. Movement Disorders, 8, 501–506.Google Scholar
Solla, P., Cannas, A., Floris, G. L., et al. (2011). Behavioral, neuropsychiatric and cognitive disorders in Parkinson’s disease patients with and without motor complications. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 35, 1009–1013.Google Scholar
Solla, P., Cannas, A., Ibba, F. C., et al. (2012). Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson’s disease. Journal of the Neurological Sciences, 323, 33–39.Google Scholar
Sproesser, E., Viana, M. A., Quagliato, E. M. and De Souza, E. A. (2010). The effect of psychotherapy in patients with PD: a controlled study. Parkinsonism & Related Disorders, 16, 298–300.Google Scholar
Stefanova, E., Ziropadja, L., Petrović, M., Stojković, T. and Kostić, V. (2013). Screening for anxiety symptoms in Parkinson disease: a cross-sectional study. Journal of Geriatric Psychiatry and Neurology, 26, 34–40.Google Scholar
Stein, M. B., Heuser, I. J., Juncos, J. L. and Uhde, T. W. (1990). Anxiety disorders in patients with Parkinson’s disease. American Journal of Psychiatry, 147, 217–220.Google Scholar
Svetel, M., Pekmezovic, T., Markovic, V., et al. (2013). No association between brain-derived neurotrophic factor G196A polymorphism and clinical features of Parkinson’s disease. European Neurology, 70, 257–262.CrossRefGoogle ScholarPubMed
Sylvester, C. M., Corbetta, M., Raichle, M. E., et al. (2012). Functional network dysfunction in anxiety and anxiety disorders. Trends in Neurosciences, 35, 527–535.Google Scholar
Tarczy, M. and Szombathelyi, E. (1998). Depression in Parkinson’s disease with special regard to anxiety: experiences with paroxetine treatment [abstract]. Movement Disorders, 13, 275.Google Scholar
Tessitore, A., Hariri, A. R., Fera, F., et al. (2002). Dopamine modulates the response of the human amygdala: a study in Parkinson’s disease. Journal of Neuroscience, 22, 9099–9103.Google Scholar
Tinaz, S., Courtney, M. G. and Stern, C. E. (2011). Focal cortical and subcortical atrophy in early Parkinson’s disease. Movement Disorders, 26, 436–441.Google Scholar
Trend, P., Kaye, J., Gage, H., Owen, C. and Wade, D. (2002). Short-term effectiveness of intensive multidisciplinary rehabilitation for people with Parkinson’s disease and their carers. Clinical Rehabilitation, 16, 717–725.Google Scholar
Troeung, L., Egan, S. J. and Gasson, N. (2014). A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson’s disease. BMC Psychiatry, 14, 19.Google Scholar
Veazey, C., Cook, K. F., Stanley, M., Lai, E. C. and Kunik, M. E. (2009). Telephone-administered cognitive behavioral therapy: a case study of anxiety and depression in Parkinson’s disease. Journal of Clinical Psychology in Medical Settings, 16, 243–253.Google Scholar
Vriend, C., Boedhoe, P. S., Rutten, S., et al. (2016). A smaller amygdala is associated with anxiety in Parkinson’s disease: a combined FreeSurfer-VBM study. Journal of Neurology, Neurosurgery, and Psychiatry, 87, 493–500.Google Scholar
Wade, D. T., Gage, H., Owen, C., Trend, P., Grossmith, C. and Kaye, J. (2003). Multidisciplinary rehabilitation for people with Parkinson’s disease: a randomised controlled study. Journal of Neurology, Neurosurgery, and Psychiatry, 74, 158–162.Google Scholar
Weintraub, D., Moberg, P. J., Duda, J. E., Katz, I. R. and Stern, M. B. (2004). Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. Journal of the American Geriatrics Society, 52, 784–788.Google Scholar
Weintraub, D., Newberg, A. B., Cary, M. S., et al. (2005). Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. Journal of Nuclear Medicine, 46, 227–232.Google Scholar
Weisskopf, M. G., Chen, H., Schwarzschild, M. A., Kawachi, I. and Ascherio, A. (2003). Prospective study of phobic anxiety and risk of Parkinson’s disease. Movement Disorders, 18, 646–651.Google Scholar
Wen, M. C., Chan, L. L., Tan, L. C. and Tan, E. K. (2016). Depression, anxiety, and apathy in Parkinson’s disease: insights from neuroimaging studies. European Journal of Neurology, 23, 1001–1019.Google Scholar
Yamakado, H., Moriwaki, Y., Yamasaki, N., et al. (2012). Alpha-synuclein BAC transgenic mice as a model for Parkinson’s disease manifested decreased anxiety-like behavior and hyperlocomotion. Neuroscience Research, 73, 173–177.Google Scholar
Yang, S., Sajatovic, M. and Walter, B. L. (2012). Psychosocial interventions for depression and anxiety in Parkinson’s disease. Journal of Geriatric Psychiatry and Neurology, 25, 113–121.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×